AMMD Starts Implant Registry - Analyst Blog
21 June 2011 - 1:24AM
Zacks
Leading pelvic-health devices maker American Medical
Systems (AMMD) recently initiated a large-scale global
registry of penile prosthetic outcomes. The new registry, dubbed
PROPPER (Prospective Registry of Outcomes with Penile Prosthesis
for Erectile Restoration), is managed by a crew of eminent
urologists looking to better characterize patient satisfaction
associated with modern penile prosthetic implants.
The multi-year company-sponsored PROPPER registry, essentially
the first-of-its-kind, has been designed to better understand the
real-world outcomes of penile implant surgery to treat erectile
dysfunction (“ED”). The registry is expected to enroll more than
1,000 ED patients recommended for penile prosthesis by their
physicians.
The research, which will initially engage ten sites, will
involve a
prospective measure of patient responses by investigating
physicians at regular intervals (over a 1-5
year period) using questionnaires and electronic data
collection.
Researchers have identified several key parameters for the
study, including device effectiveness, durability, complications,
patient satisfaction and quality of life. Results from the PROPPER
registry (with the initial outcomes) will be publicized in
2013.
American Medical is a world leader in manufacturing medical
devices and procedures for treating health problems of both men and
women. The company competes with larger players like Boston
Scientific (BSX), Johnson & Johnson
(JNJ) and C.R. Bard (BCR).
American Medical derives nearly half of its revenues from its
Men’s Health business, which comprises erectile restoration, male
continence and prostate treatments. Revenues from Men’s Health
continue to be boosted by higher demand for the male continence and
erectile restoration product lines.
While American Medical has a dominant position in both male and
female incontinence markets, it is exposed to a significant
reimbursement risk and its European markets are yet to fully
recover from the macroeconomic softness.
American Medical is slated to be acquired by specialty
healthcare solutions company Endo Pharmaceuticals
(ENDP) in the third quarter of 2011. Under the deal, announced in
April 2011, Endo Pharmaceuticals will buy the company for $2.9
billion or $30.00 per share in cash. The consideration includes the
assumption of $312 million of debt.
The transaction has been approved by the Boards of both
companies and is subject to the approval of American Medical’s
shareholders, antitrust clearance and attainment of other closing
conditions. Currently, we have a Neutral rating on American
Medical.
AMER MED SYS (AMMD): Free Stock Analysis Report
BARD C R INC (BCR): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
ENDO PHARMACEUT (ENDP): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
Zacks Investment Research
American Medical Systems (NASDAQ:AMMD)
Historical Stock Chart
From May 2024 to Jun 2024
American Medical Systems (NASDAQ:AMMD)
Historical Stock Chart
From Jun 2023 to Jun 2024